In This Article:
-
Total Revenue: $270 million, an increase of $24 million from Q1 2024, and a decrease of $37 million from Q4 2024.
-
Product Revenue: $145 million, an increase of $12 million over Q1 2024, and a decrease of $37 million compared to Q4 2024.
-
Service Revenue: $125 million, an increase of $12 million over Q1 2024, and flat compared to Q4 2024.
-
Non-GAAP Gross Margin: 42.1%, a decrease of 530 basis points from the prior quarter.
-
GAAP Earnings Per Share: Loss of $0.15 per share, compared to a loss of $0.34 per share in Q1 2024, and a profit of $0.34 per share in the prior quarter.
-
Non-GAAP Earnings Per Share: $0.26, compared to $0.03 per share in Q1 2024, and $0.60 per share in the prior quarter.
-
Non-GAAP EBITDA: $24 million, an increase of $13 million from Q1 2024, and a decrease of $23 million from the previous quarter.
-
Cash and Cash Equivalents: $387 million, up from $369 million as of December 31, 2024.
-
Free Cash Flow: $10 million during Q1 2025.
-
Inventories: $91 million, an increase of $2 million from the prior quarter, and a decrease of $12 million from March 31, 2024.
Release Date: May 06, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Omnicell Inc (NASDAQ:OMCL) reported a solid first quarter with total revenue of $270 million, an increase of $24 million from the first quarter of 2024.
-
The company saw growth in its recurring revenue, driven by demand for its medication management platform and XT Amplify program.
-
Non-GAAP earnings per share improved to $0.26 from $0.03 in the same period last year.
-
Omnicell Inc (NASDAQ:OMCL) continues to see strong customer interest in its long-term innovation roadmap, including the OmniSphere cloud-based platform.
-
The company reported strong free cash flow of $10 million during the first quarter of 2025, with cash and cash equivalents increasing to $387 million.
Negative Points
-
Omnicell Inc (NASDAQ:OMCL) faced a GAAP loss of $0.15 per share in the first quarter of 2025, compared to a profit in the prior quarter.
-
Non-GAAP gross margin decreased by 530 basis points from the prior quarter due to lower product revenue volumes and seasonal expenses.
-
The company anticipates a $40 million impact on non-GAAP EBITDA for 2025 due to tariffs, particularly on China-based products.
-
Omnicell Inc (NASDAQ:OMCL) had to adjust its full-year 2025 non-GAAP EBITDA and earnings per share guidance due to the expected tariff impact.
-
The company is facing challenges in its supply chain, with a significant portion of components sourced from China, leading to tariff exposure.